Access
To read this story in full you will need to login or make a payment (see right).
Correspondence
Nature 440, 605 (30 March 2006) | doi:10.1038/440605d; Published online 29 March 2006
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
Junior Research Groups (W1 / W2)
- Cluster of Excellence "Multimodal Computing and Interaction"
- Saarbruecken Germany
Leadership Fellowships
- University of Oxford
- Oxford United Kingdom
Populations who test drugs should benefit from them
Sanjay Basu1, Jason Andrews1 & Duncan Smith-Rohrberg1
- Yale University School of Medicine, 129 York Street, New Haven, Connecticut 06511, USA
Paul Herrling, in his Commentary article "Experiments in social responsibility" (Nature 439, 267–268; 2006), describes pharmaceutical companies moving towards a more progressive approach to drug development and distribution in poor countries. But it is important to note that, even when research in developing nations leads to effective treatments, there is still the danger of local populations being exploited.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Gender and Strain Influence on Neurogenesis in Dentate Gyrus of Young RatsJournal of Cerebral Blood Flow & Metabolism Original Article
Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experienceBone Marrow Transplantation Original Article
EP1- and EP3-Receptors Mediate Prostaglandin E2-Induced Constriction of Porcine Large Cerebral ArteriesJournal of Cerebral Blood Flow & Metabolism Original Article
